{"entity":{"type":"insider","cik":"0001408500","url":"/insider/0001408500","json_url":"/insider/0001408500.json","name":"Cearnal Martin E","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":174,"n_filings":8,"first":"2021-06-08","last":"2022-01-07","span_basis":"filed_date"},"name_variants":[{"name":"Cearnal Martin E","source":"filing","n_filings":8,"first_seen":"2021-06-08","last_seen":"2022-01-07"}],"transactions":[{"id":6202790,"accession":"0001209191-22-002447","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-14","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":314.0,"shares_display":"314","price_per_share":4.33,"price_display":"4.33","price_state":"stated","total_value":1359.62,"total_display":"1,359.62","total_whole":"1,360","shares_owned_after":178473.0,"shares_owned_after_display":"178,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-20","filed_date":"2022-01-07","scope":"insider"},{"id":6202786,"accession":"0001209191-22-002447","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-13","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":240.0,"shares_display":"240","price_per_share":4.17,"price_display":"4.17","price_state":"stated","total_value":1000.8,"total_display":"1,000.80","total_whole":"1,001","shares_owned_after":178159.0,"shares_owned_after_display":"178,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-17","filed_date":"2022-01-07","scope":"insider"},{"id":6202774,"accession":"0001209191-22-002447","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-12","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":240.0,"shares_display":"240","price_per_share":4.53,"price_display":"4.53","price_state":"stated","total_value":1087.2,"total_display":"1,087.20","total_whole":"1,087","shares_owned_after":177919.0,"shares_owned_after_display":"177,919","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-16","filed_date":"2022-01-07","scope":"insider"},{"id":6202769,"accession":"0001209191-22-002447","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-11","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":4.29,"price_display":"4.29","price_state":"stated","total_value":858.0,"total_display":"858.00","total_whole":"858","shares_owned_after":177679.0,"shares_owned_after_display":"177,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-15","filed_date":"2022-01-07","scope":"insider"},{"id":6202765,"accession":"0001209191-22-002447","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-10","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":4.28,"price_display":"4.28","price_state":"stated","total_value":856.0,"total_display":"856.00","total_whole":"856","shares_owned_after":177479.0,"shares_owned_after_display":"177,479","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-14","filed_date":"2022-01-07","scope":"insider"},{"id":6202761,"accession":"0001209191-22-002447","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-9","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":4.36,"price_display":"4.36","price_state":"stated","total_value":872.0,"total_display":"872.00","total_whole":"872","shares_owned_after":177279.0,"shares_owned_after_display":"177,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-13","filed_date":"2022-01-07","scope":"insider"},{"id":6202756,"accession":"0001209191-22-002447","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-8","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":4.82,"price_display":"4.82","price_state":"stated","total_value":433.8,"total_display":"433.80","total_whole":"434","shares_owned_after":177079.0,"shares_owned_after_display":"177,079","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2022-01-07","scope":"insider"},{"id":6202752,"accession":"0001209191-22-002447","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-7","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":5.81,"price_display":"5.81","price_state":"stated","total_value":522.9,"total_display":"522.90","total_whole":"523","shares_owned_after":176989.0,"shares_owned_after_display":"176,989","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-09","filed_date":"2022-01-07","scope":"insider"},{"id":6202749,"accession":"0001209191-22-002447","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-6","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":6.15,"price_display":"6.15","price_state":"stated","total_value":553.5,"total_display":"553.50","total_whole":"554","shares_owned_after":176899.0,"shares_owned_after_display":"176,899","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-08","filed_date":"2022-01-07","scope":"insider"},{"id":6202745,"accession":"0001209191-22-002447","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-5","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":5.61,"price_display":"5.61","price_state":"stated","total_value":504.9,"total_display":"504.90","total_whole":"505","shares_owned_after":176809.0,"shares_owned_after_display":"176,809","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-07","filed_date":"2022-01-07","scope":"insider"},{"id":6202739,"accession":"0001209191-22-002447","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-4","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":4.46,"price_display":"4.46","price_state":"stated","total_value":401.4,"total_display":"401.40","total_whole":"401","shares_owned_after":176719.0,"shares_owned_after_display":"176,719","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-06","filed_date":"2022-01-07","scope":"insider"},{"id":6202735,"accession":"0001209191-22-002447","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-3","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":4.47,"price_display":"4.47","price_state":"stated","total_value":402.3,"total_display":"402.30","total_whole":"402","shares_owned_after":176629.0,"shares_owned_after_display":"176,629","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-03","filed_date":"2022-01-07","scope":"insider"},{"id":6202730,"accession":"0001209191-22-002447","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-2","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":3.84,"price_display":"3.84","price_state":"stated","total_value":345.6,"total_display":"345.60","total_whole":"346","shares_owned_after":176539.0,"shares_owned_after_display":"176,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-02","filed_date":"2022-01-07","scope":"insider"},{"id":6202724,"accession":"0001209191-22-002447","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-002447","line_url":"/filing/0001209191-22-002447#line-1","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":90.0,"shares_display":"90","price_per_share":4.14,"price_display":"4.14","price_state":"stated","total_value":372.6,"total_display":"372.60","total_whole":"373","shares_owned_after":176449.0,"shares_owned_after_display":"176,449","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-01","filed_date":"2022-01-07","scope":"insider"},{"id":4148730,"accession":"0001209191-21-067878","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-21","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175.0,"shares_display":"175","price_per_share":4.61,"price_display":"4.61","price_state":"stated","total_value":806.75,"total_display":"806.75","total_whole":"807","shares_owned_after":176359.0,"shares_owned_after_display":"176,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-30","filed_date":"2021-12-03","scope":"insider"},{"id":4148723,"accession":"0001209191-21-067878","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-20","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175.0,"shares_display":"175","price_per_share":2.23,"price_display":"2.23","price_state":"stated","total_value":390.25,"total_display":"390.25","total_whole":"390","shares_owned_after":176184.0,"shares_owned_after_display":"176,184","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-29","filed_date":"2021-12-03","scope":"insider"},{"id":4148722,"accession":"0001209191-21-067878","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-19","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175.0,"shares_display":"175","price_per_share":2.26,"price_display":"2.26","price_state":"stated","total_value":395.5,"total_display":"395.50","total_whole":"396","shares_owned_after":176009.0,"shares_owned_after_display":"176,009","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-26","filed_date":"2021-12-03","scope":"insider"},{"id":4148719,"accession":"0001209191-21-067878","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-18","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175.0,"shares_display":"175","price_per_share":2.31,"price_display":"2.31","price_state":"stated","total_value":404.25,"total_display":"404.25","total_whole":"404","shares_owned_after":175834.0,"shares_owned_after_display":"175,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-24","filed_date":"2021-12-03","scope":"insider"},{"id":4148716,"accession":"0001209191-21-067878","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-17","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.29,"price_display":"2.29","price_state":"stated","total_value":240.45,"total_display":"240.45","total_whole":"240","shares_owned_after":175659.0,"shares_owned_after_display":"175,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-23","filed_date":"2021-12-03","scope":"insider"},{"id":4148712,"accession":"0001209191-21-067878","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-16","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.35,"price_display":"2.35","price_state":"stated","total_value":246.75,"total_display":"246.75","total_whole":"247","shares_owned_after":175554.0,"shares_owned_after_display":"175,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-22","filed_date":"2021-12-03","scope":"insider"},{"id":4148709,"accession":"0001209191-21-067878","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-15","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.55,"price_display":"2.55","price_state":"stated","total_value":267.75,"total_display":"267.75","total_whole":"268","shares_owned_after":175449.0,"shares_owned_after_display":"175,449","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-19","filed_date":"2021-12-03","scope":"insider"},{"id":4148706,"accession":"0001209191-21-067878","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-14","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.58,"price_display":"2.58","price_state":"stated","total_value":270.9,"total_display":"270.90","total_whole":"271","shares_owned_after":175344.0,"shares_owned_after_display":"175,344","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-18","filed_date":"2021-12-03","scope":"insider"},{"id":4148703,"accession":"0001209191-21-067878","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-13","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.58,"price_display":"2.58","price_state":"stated","total_value":270.9,"total_display":"270.90","total_whole":"271","shares_owned_after":175239.0,"shares_owned_after_display":"175,239","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-17","filed_date":"2021-12-03","scope":"insider"},{"id":4148701,"accession":"0001209191-21-067878","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-12","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.66,"price_display":"2.66","price_state":"stated","total_value":279.3,"total_display":"279.30","total_whole":"279","shares_owned_after":175134.0,"shares_owned_after_display":"175,134","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-16","filed_date":"2021-12-03","scope":"insider"},{"id":4148697,"accession":"0001209191-21-067878","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-11","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":284.55,"total_display":"284.55","total_whole":"285","shares_owned_after":175029.0,"shares_owned_after_display":"175,029","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-15","filed_date":"2021-12-03","scope":"insider"},{"id":4148694,"accession":"0001209191-21-067878","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-10","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.67,"price_display":"2.67","price_state":"stated","total_value":280.35,"total_display":"280.35","total_whole":"280","shares_owned_after":174924.0,"shares_owned_after_display":"174,924","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-12","filed_date":"2021-12-03","scope":"insider"},{"id":4148691,"accession":"0001209191-21-067878","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-9","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.83,"price_display":"2.83","price_state":"stated","total_value":297.15,"total_display":"297.15","total_whole":"297","shares_owned_after":174819.0,"shares_owned_after_display":"174,819","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-11","filed_date":"2021-12-03","scope":"insider"},{"id":4148688,"accession":"0001209191-21-067878","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-8","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.94,"price_display":"2.94","price_state":"stated","total_value":308.7,"total_display":"308.70","total_whole":"309","shares_owned_after":174714.0,"shares_owned_after_display":"174,714","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-10","filed_date":"2021-12-03","scope":"insider"},{"id":4148687,"accession":"0001209191-21-067878","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-7","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":3.21,"price_display":"3.21","price_state":"stated","total_value":337.05,"total_display":"337.05","total_whole":"337","shares_owned_after":174609.0,"shares_owned_after_display":"174,609","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-09","filed_date":"2021-12-03","scope":"insider"},{"id":4148684,"accession":"0001209191-21-067878","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-6","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.95,"price_display":"2.95","price_state":"stated","total_value":309.75,"total_display":"309.75","total_whole":"310","shares_owned_after":174504.0,"shares_owned_after_display":"174,504","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-08","filed_date":"2021-12-03","scope":"insider"},{"id":4148681,"accession":"0001209191-21-067878","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-5","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":284.55,"total_display":"284.55","total_whole":"285","shares_owned_after":174399.0,"shares_owned_after_display":"174,399","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-05","filed_date":"2021-12-03","scope":"insider"},{"id":4148678,"accession":"0001209191-21-067878","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-4","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.73,"price_display":"2.73","price_state":"stated","total_value":286.65,"total_display":"286.65","total_whole":"287","shares_owned_after":174294.0,"shares_owned_after_display":"174,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-04","filed_date":"2021-12-03","scope":"insider"},{"id":4148676,"accession":"0001209191-21-067878","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-3","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":284.55,"total_display":"284.55","total_whole":"285","shares_owned_after":174189.0,"shares_owned_after_display":"174,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-03","filed_date":"2021-12-03","scope":"insider"},{"id":4148673,"accession":"0001209191-21-067878","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-2","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.63,"price_display":"2.63","price_state":"stated","total_value":276.15,"total_display":"276.15","total_whole":"276","shares_owned_after":174084.0,"shares_owned_after_display":"174,084","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-02","filed_date":"2021-12-03","scope":"insider"},{"id":4148670,"accession":"0001209191-21-067878","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-067878","line_url":"/filing/0001209191-21-067878#line-1","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.67,"price_display":"2.67","price_state":"stated","total_value":280.35,"total_display":"280.35","total_whole":"280","shares_owned_after":173979.0,"shares_owned_after_display":"173,979","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-12-03","scope":"insider"},{"id":4492423,"accession":"0001209191-21-063217","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-21","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.72,"price_display":"2.72","price_state":"stated","total_value":285.6,"total_display":"285.60","total_whole":"286","shares_owned_after":173874.0,"shares_owned_after_display":"173,874","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-29","filed_date":"2021-11-05","scope":"insider"},{"id":4492415,"accession":"0001209191-21-063217","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-20","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":274.05,"total_display":"274.05","total_whole":"274","shares_owned_after":173769.0,"shares_owned_after_display":"173,769","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-28","filed_date":"2021-11-05","scope":"insider"},{"id":4492408,"accession":"0001209191-21-063217","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-19","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":274.05,"total_display":"274.05","total_whole":"274","shares_owned_after":173664.0,"shares_owned_after_display":"173,664","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-27","filed_date":"2021-11-05","scope":"insider"},{"id":4492402,"accession":"0001209191-21-063217","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-18","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.64,"price_display":"2.64","price_state":"stated","total_value":277.2,"total_display":"277.20","total_whole":"277","shares_owned_after":173559.0,"shares_owned_after_display":"173,559","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-26","filed_date":"2021-11-05","scope":"insider"},{"id":4492400,"accession":"0001209191-21-063217","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-17","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.64,"price_display":"2.64","price_state":"stated","total_value":277.2,"total_display":"277.20","total_whole":"277","shares_owned_after":173454.0,"shares_owned_after_display":"173,454","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-25","filed_date":"2021-11-05","scope":"insider"},{"id":4492397,"accession":"0001209191-21-063217","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-16","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.66,"price_display":"2.66","price_state":"stated","total_value":279.3,"total_display":"279.30","total_whole":"279","shares_owned_after":173349.0,"shares_owned_after_display":"173,349","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-22","filed_date":"2021-11-05","scope":"insider"},{"id":4487888,"accession":"0001209191-21-063217","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-15","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.65,"price_display":"2.65","price_state":"stated","total_value":278.25,"total_display":"278.25","total_whole":"278","shares_owned_after":173244.0,"shares_owned_after_display":"173,244","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-21","filed_date":"2021-11-05","scope":"insider"},{"id":4487878,"accession":"0001209191-21-063217","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-14","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.63,"price_display":"2.63","price_state":"stated","total_value":276.15,"total_display":"276.15","total_whole":"276","shares_owned_after":173139.0,"shares_owned_after_display":"173,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-20","filed_date":"2021-11-05","scope":"insider"},{"id":4487872,"accession":"0001209191-21-063217","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-13","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.76,"price_display":"2.76","price_state":"stated","total_value":289.8,"total_display":"289.80","total_whole":"290","shares_owned_after":173034.0,"shares_owned_after_display":"173,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-19","filed_date":"2021-11-05","scope":"insider"},{"id":4487860,"accession":"0001209191-21-063217","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-12","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":288.75,"total_display":"288.75","total_whole":"289","shares_owned_after":172929.0,"shares_owned_after_display":"172,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-18","filed_date":"2021-11-05","scope":"insider"},{"id":4487854,"accession":"0001209191-21-063217","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-11","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.76,"price_display":"2.76","price_state":"stated","total_value":289.8,"total_display":"289.80","total_whole":"290","shares_owned_after":172824.0,"shares_owned_after_display":"172,824","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-15","filed_date":"2021-11-05","scope":"insider"},{"id":4487848,"accession":"0001209191-21-063217","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-10","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.81,"price_display":"2.81","price_state":"stated","total_value":295.05,"total_display":"295.05","total_whole":"295","shares_owned_after":172719.0,"shares_owned_after_display":"172,719","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-11-05","scope":"insider"},{"id":4487842,"accession":"0001209191-21-063217","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-9","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":284.55,"total_display":"284.55","total_whole":"285","shares_owned_after":172614.0,"shares_owned_after_display":"172,614","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-13","filed_date":"2021-11-05","scope":"insider"},{"id":4487836,"accession":"0001209191-21-063217","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-8","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":284.55,"total_display":"284.55","total_whole":"285","shares_owned_after":172509.0,"shares_owned_after_display":"172,509","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-12","filed_date":"2021-11-05","scope":"insider"},{"id":4487831,"accession":"0001209191-21-063217","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-063217","line_url":"/filing/0001209191-21-063217#line-7","is_derivative":false,"issuer_cik":"0001087294","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","issuer_ticker":"CPIX","issuer_name_source":null,"issuer_url":"/issuer/0001087294","owner_cik":"0001408500","owner_name":"Cearnal Martin E","owner_display_name":"Cearnal Martin E","owner_url":"/insider/0001408500","role":"Director, Officer (Sr VP/Chief Commercial Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP/Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":105.0,"shares_display":"105","price_per_share":2.73,"price_display":"2.73","price_state":"stated","total_value":286.65,"total_display":"286.65","total_whole":"287","shares_owned_after":172404.0,"shares_owned_after_display":"172,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-11","filed_date":"2021-11-05","scope":"insider"}],"collapsed":true,"next_cursor":"2021-10-11|4487831","ledger_fault":false,"count":{"value":174,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":174,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":174},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001087294","name":"CUMBERLAND PHARMACEUTICALS INC","url":"/issuer/0001087294","role":"Director, Officer (Sr VP/Chief Commercial Officer)","n_filings":8,"first_seen":"2021-06-08","last_seen":"2022-01-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001408500","retrieved_at":"2026-08-25T22:07:21+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}